Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

OB GYN new masthead 1

OB/GYN Clinical Alert – January 1, 2023

January 1, 2023

View Issues

  • A Simple Intervention to Reduce Surgical Site Infections?

    This multicenter, cluster randomized trial in Benin, Ghana, India, Mexico, Nigeria, Rwanda, and South Africa evaluated the effect of changing sterile gloves and instruments at the time of abdominal wound closure on surgical site infection (SSI) rates among adults and children undergoing both elective and emergent surgery. The SSI rate in the intervention group among 5,789 patients was 16% compared to 18.9% in the control group of 6,768 patients (adjusted risk ratio, 0.87; 95% confidence interval, 0.79-0.95).

  • Effectiveness of an Online e-Health Program in Ameliorating Postpartum Depression

    This study demonstrated that combined use of universal depression screening and MomMoodBooster2, a cognitive behavioral therapy-based e-health program, were effective tools for treating women with depression in the perinatal period.

  • Ibrexafungerp for Vulvovaginal Candidiasis

    A randomized clinical trial compared one day of oral ibrexafungerp with placebo for female patients with vulvovaginal candidiasis (VVC). It found ibrexafungerp to be safe and effective, with mild diarrhea the most common adverse event. Ibrexafungerp differs mechanistically from azoles and appears to be a promising new treatment for VVC.

  • Current and Future Options for Male Contraception

    Following the landmark Dobbs v. Jackson Women’s Health Organization decision that ended the constitutional right to abortion in the United States, the importance of contraception has grown. This article summarizes the existing male contraceptive options and reviews the status of future ones.